1. Home
  2. XNET vs PROK Comparison

XNET vs PROK Comparison

Compare XNET & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xunlei Limited

XNET

Xunlei Limited

HOLD

Current Price

$4.93

Market Cap

358.4M

Sector

Technology

ML Signal

HOLD

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$1.89

Market Cap

316.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XNET
PROK
Founded
2003
2015
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
358.4M
316.0M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
XNET
PROK
Price
$4.93
$1.89
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.40
AVG Volume (30 Days)
219.1K
1.1M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$893,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.29
N/A
Revenue Growth
N/A
1075.00
52 Week Low
$4.52
$1.30
52 Week High
$11.03
$3.48

Technical Indicators

Market Signals
Indicator
XNET
PROK
Relative Strength Index (RSI) 42.00 66.58
Support Level $4.78 $1.56
Resistance Level $6.09 $1.96
Average True Range (ATR) 0.19 0.12
MACD 0.01 0.05
Stochastic Oscillator 35.71 95.93

Price Performance

Historical Comparison
XNET
PROK

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: